ECSP20039623A - Anticuerpos anti alfa-sinucleína - Google Patents

Anticuerpos anti alfa-sinucleína

Info

Publication number
ECSP20039623A
ECSP20039623A ECSENADI202039623A ECDI202039623A ECSP20039623A EC SP20039623 A ECSP20039623 A EC SP20039623A EC SENADI202039623 A ECSENADI202039623 A EC SENADI202039623A EC DI202039623 A ECDI202039623 A EC DI202039623A EC SP20039623 A ECSP20039623 A EC SP20039623A
Authority
EC
Ecuador
Prior art keywords
alpha
antibodies
sinuclein
alpha synuclein
present
Prior art date
Application number
ECSENADI202039623A
Other languages
English (en)
Inventor
Patrick Downey
David James Mcmillan
Terence Seward Baker
Ralph Adams
Kerry Louise Tyson
Daniel John Lightwood
Lichtervelde Lorenzo De
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of ECSP20039623A publication Critical patent/ECSP20039623A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a alfa sinucleína y fragmentos de la misma capaces de unirse a alfa sinucleína como un monómero y en fibrillas y prevenir la agregación de alfa sinucleína inducida por fibrillas de alfa sinucleína. Los anticuerpos de la presente invención son para uso en el tratamiento de alfa sinucleinopatías, incluyendo la enfermedad de Parkinson.
ECSENADI202039623A 2017-12-15 2020-07-14 Anticuerpos anti alfa-sinucleína ECSP20039623A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720975.0A GB201720975D0 (en) 2017-12-15 2017-12-15 Anti-alpha synuclein antibodies

Publications (1)

Publication Number Publication Date
ECSP20039623A true ECSP20039623A (es) 2020-08-31

Family

ID=61009086

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202039623A ECSP20039623A (es) 2017-12-15 2020-07-14 Anticuerpos anti alfa-sinucleína

Country Status (26)

Country Link
US (2) US11261242B2 (es)
EP (1) EP3724224A1 (es)
JP (2) JP7292279B2 (es)
KR (1) KR102789446B1 (es)
CN (1) CN111479826B (es)
AR (1) AR115192A1 (es)
AU (1) AU2018382530B2 (es)
BR (1) BR112020010504A2 (es)
CA (1) CA3083199A1 (es)
CL (1) CL2020001605A1 (es)
EA (1) EA202091478A1 (es)
EC (1) ECSP20039623A (es)
GB (1) GB201720975D0 (es)
IL (1) IL275187B2 (es)
MA (1) MA51135A (es)
MX (2) MX2020005691A (es)
MY (1) MY205948A (es)
PE (1) PE20201061A1 (es)
PH (1) PH12020551007A1 (es)
SG (1) SG11202004502SA (es)
TN (2) TN2021000169A1 (es)
TW (2) TWI801469B (es)
UA (1) UA126295C2 (es)
UY (1) UY38010A (es)
WO (1) WO2019115674A1 (es)
ZA (2) ZA202003542B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
GB201720975D0 (en) * 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
WO2020079113A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
WO2021055881A1 (en) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
US20230025256A1 (en) * 2019-12-04 2023-01-26 Simon Friedman Protein blocking assembly and methods of making and using
KR20240176098A (ko) * 2023-06-14 2024-12-24 경상국립대학교산학협력단 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2002221132A1 (en) 2000-12-13 2002-07-01 Taisho Pharmaceutical Co. Ltd. Novel antibody
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
PL1633189T3 (pl) 2003-05-19 2017-12-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami lewy'ego
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
PL2118300T3 (pl) 2007-02-23 2015-11-30 Prothena Biosciences Ltd Zapobieganie i leczenie synukleinopatii i amyloidozy
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
LT3067066T (lt) * 2007-02-23 2019-06-25 Prothena Biosciences Limited Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas
DK2282758T3 (en) 2008-04-29 2019-02-25 Bioarctic Ab ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2539366B1 (en) * 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
US9910049B2 (en) 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein
CN103796679B (zh) * 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
HRP20230065T1 (hr) * 2011-10-28 2023-03-03 Prothena Biosciences Limited Humanizirana protutijela koja prepoznaju alfa-sinuklein
SG11201404321YA (en) 2012-01-27 2014-08-28 Neotope Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
US12156912B2 (en) 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
CA2924268C (en) 2013-11-21 2021-05-18 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10155030B2 (en) 2014-05-23 2018-12-18 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
EP3191599B1 (en) 2014-09-11 2023-08-02 Board Of Regents Of the University Of Texas System Detection of misfolded proteins
US9732148B2 (en) 2014-10-16 2017-08-15 Genentech, Inc. Anti-α-synuclein antibodies and methods of use
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP6989927B2 (ja) 2015-08-25 2022-02-03 プロセナ バイオサイエンシーズ リミテッド リン酸化アルファ－シヌクレインを検出するための方法
US10639383B2 (en) 2015-11-23 2020-05-05 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
EP3440225A4 (en) 2016-04-06 2020-03-11 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
CN109475616B (zh) 2016-06-02 2022-10-18 麦迪穆有限责任公司 针对α-突触核蛋白的抗体及其用途
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
WO2018039147A1 (en) 2016-08-23 2018-03-01 The Johns Hopkins University THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
US20180134777A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (11D12)
US20180134776A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (4H6)
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
CA3036592A1 (en) 2016-12-12 2018-06-21 The Michael J. Fox Foundation For Parkinson's Research Antibodies to human alpha-synuclein
EP3555127B1 (en) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
JP2020504151A (ja) 2017-01-09 2020-02-06 カリフォルニア インスティチュート オブ テクノロジー パーキンソン病の診断および治療薬における腸内微生物叢の使用
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
TW201901153A (zh) 2017-05-16 2019-01-01 美商安培恩股份有限公司 折疊錯誤之ｔａｕ蛋白的檢測及檢測折疊錯誤之ｔａｕ蛋白的套組
WO2018237338A1 (en) 2017-06-23 2018-12-27 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies

Also Published As

Publication number Publication date
EP3724224A1 (en) 2020-10-21
GB201720975D0 (en) 2018-01-31
ZA202103456B (en) 2023-01-25
PH12020551007A1 (en) 2021-08-16
KR20200099160A (ko) 2020-08-21
KR102789446B1 (ko) 2025-04-01
SG11202004502SA (en) 2020-06-29
CA3083199A1 (en) 2019-06-20
AU2018382530B2 (en) 2025-04-17
US20220220192A1 (en) 2022-07-14
US20210107971A1 (en) 2021-04-15
CL2020001605A1 (es) 2020-08-28
RU2020123274A (ru) 2022-01-17
JP7627300B2 (ja) 2025-02-05
TN2021000169A1 (en) 2023-04-04
CN111479826B (zh) 2024-10-29
MX2024013356A (es) 2024-12-06
EA202091478A1 (ru) 2020-09-04
RU2020123274A3 (es) 2022-01-17
TWI801469B (zh) 2023-05-11
PE20201061A1 (es) 2020-10-16
TN2020000069A1 (en) 2022-01-06
TW201930354A (zh) 2019-08-01
IL275187B2 (en) 2026-05-01
MX2020005691A (es) 2020-08-20
UA126295C2 (uk) 2022-09-14
JP2023127585A (ja) 2023-09-13
CN111479826A (zh) 2020-07-31
JP7292279B2 (ja) 2023-06-16
US11261242B2 (en) 2022-03-01
TW202332692A (zh) 2023-08-16
JP2021509012A (ja) 2021-03-18
WO2019115674A1 (en) 2019-06-20
US12545720B2 (en) 2026-02-10
IL275187A (en) 2020-07-30
AR115192A1 (es) 2020-12-09
IL275187B1 (en) 2026-01-01
UY38010A (es) 2019-07-31
MA51135A (fr) 2021-03-24
MY205948A (en) 2024-11-21
ZA202003542B (en) 2022-12-21
AU2018382530A1 (en) 2020-06-18
BR112020010504A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
CL2020001607A1 (es) Anticuerpos anti alfa-sinucleína.
CL2020001605A1 (es) Anticuerpos anti alfa-sinucleína.
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
DOP2022000172A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
CO2017002719A2 (es) Anticuerpos anti-glucagón
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CR20170060A (es) Anticuerpos anti tigit
CL2017000515A1 (es) Cd123 agentes enlazadores y su uso
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
MX2015012576A (es) Composiciones a base de nanoparticulas.
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
MX2016001236A (es) Anticuerpos anti-fgfr2iiib afucosilados.
AR102658A1 (es) Composición para el tratamiento de telas
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017009294A (es) Tratamiento de pacientes pediatricos con diabetes mellitus de tipo 2 con lixisenatida.
BR112019023742A2 (pt) anticorpos anti-trkb
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
AR114808A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA
AR120118A2 (es) Anticuerpos anti tigit
UY36985A (es) Agonistas de unión para el tratamiento de trastornos neurológicos y otros trastornos
MX2018003317A (es) Celulas t modificadas que tienen propiedades anti-fuctacticas y sus usos.